The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus

[1]  Gabriëlle H S Buitendijk,et al.  High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control , 2013, Diabetes Care.

[2]  G. Umpierrez,et al.  The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. , 2013, Translational research : the journal of laboratory and clinical medicine.

[3]  Yukiko Kawasaki,et al.  Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. , 2013, Diabetes research and clinical practice.

[4]  Wendy J Mack,et al.  Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[5]  L. Poretsky,et al.  Thiazolidinediones (TZDs) Affect Osteoblast Viability and Biomarkers Independently of the TZD Effects on Aromatase , 2012, Hormone and Metabolic Research.

[6]  Jeffrey A. Johnson,et al.  Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. , 2012, Diabetes & metabolism.

[7]  G. Demetri,et al.  A phase 1 study of efatutazone, an oral peroxisome proliferator‐activated receptor gamma agonist, administered to patients with advanced malignancies , 2012, Cancer.

[8]  E. Kang,et al.  The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone , 2012, Diabetes & metabolism journal.

[9]  Kevin Haynes,et al.  Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. , 2012, Journal of the National Cancer Institute.

[10]  P. Donnan,et al.  Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs , 2012, Diabetologia.

[11]  D. Torres,et al.  Features, diagnosis, and treatment of nonalcoholic fatty liver disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  Use of thiazolidinedione and cancer risk in Type 2 diabetes: the Hong Kong diabetes registry. , 2012, Diabetes research and clinical practice.

[13]  G. Hortobagyi,et al.  Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  L. Suva,et al.  Rosiglitazone Inhibits Bone Regeneration and Causes Significant Accumulation of Fat at Sites of New Bone Formation , 2012, Calcified Tissue International.

[15]  M. Underwood,et al.  Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice. , 2012, Current cancer drug targets.

[16]  D. Chappard,et al.  Thiazolidinediones Induce Osteocyte Apoptosis by a G Protein-coupled Receptor 40-dependent Mechanism* , 2012, The Journal of Biological Chemistry.

[17]  J. Hardies,et al.  Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease , 2012, Hepatology.

[18]  M. Lai,et al.  Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus , 2012, Hepatology.

[19]  C. Cooper,et al.  Risk of Fracture with Thiazolidinediones: Disease or Drugs? , 2012, Calcified Tissue International.

[20]  Yue-Yang Zhao,et al.  A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome , 2012, Current medical research and opinion.

[21]  K. Cusi,et al.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[22]  F. Alla,et al.  Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study , 2012, Diabetologia.

[23]  C. Tseng,et al.  Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? , 2012, Journal of the Formosan Medical Association = Taiwan yi zhi.

[24]  C. Tseng.  Pioglitazone and Bladder Cancer , 2012, Diabetes Care.

[25]  Soo Hyun Lee,et al.  Cell death is induced by ciglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) agonist, independently of PPARγ in human glioma cells. , 2012, Biochemical and biophysical research communications.

[26]  F. Sung,et al.  Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy: A Population-Based Cohort Study , 2012, The American Journal of Gastroenterology.

[27]  C. Cooper,et al.  Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs? , 2012, Pharmacoepidemiology and drug safety.

[28]  A. Hatzitolios,et al.  The Role of Insulin-Sensitizing Agents in the Treatment of Polycystic Ovary Syndrome , 2009, Drugs.

[29]  R. Andreesen,et al.  Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial , 2012, Medical Oncology.

[30]  X. Correig,et al.  Metabolomics Reveals Reduction of Metabolic Oxidation in Women with Polycystic Ovary Syndrome after Pioglitazone-Flutamide-Metformin Polytherapy , 2011, PloS one.

[31]  I. Lascombe,et al.  The Antidiabetic Drug Ciglitazone Induces High Grade Bladder Cancer Cells Apoptosis through the Up-Regulation of TRAIL , 2011, PloS one.

[32]  S. Tu,et al.  Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  N. Perico,et al.  Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. , 2011, International journal of cardiology.

[34]  C. Tseng.  Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan , 2011, Diabetologia.

[35]  Claus Christiansen,et al.  Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel‐group study in patients with type 2 diabetes on stable insulin therapy , 2011, Diabetes/metabolism research and reviews.

[36]  Adrian V. Hernández,et al.  Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[37]  Devjit Tripathy,et al.  Pioglitazone for diabetes prevention in impaired glucose tolerance. , 2011, The New England journal of medicine.

[38]  W. Bilker,et al.  Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone , 2011, Diabetes Care.

[39]  B. Yan,et al.  Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta‐analysis , 2011, Clinical endocrinology.

[40]  平野 光正.  Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome , 2011 .

[41]  G. Chrousos,et al.  Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. , 2011, Fertility and sterility.

[42]  B. Neuschwander‐Tetri,et al.  Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues , 2010, Hepatology.

[43]  A. López-Bermejo,et al.  Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months , 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[44]  Jesse C. Crosson,et al.  Thiazolidinediones and fractures: evidence from translating research into action for diabetes. , 2010, The Journal of clinical endocrinology and metabolism.

[45]  S. Haffner,et al.  Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes , 2010, Diabetes, obesity & metabolism.

[46]  R. DeFronzo,et al.  Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). , 2010, The Journal of clinical endocrinology and metabolism.

[47]  M. Burnier,et al.  Effects of the peroxisome proliferator-activated receptor (PPAR)-γ agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals , 2010, Diabetologia.

[48]  P. Giral,et al.  Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.

[49]  G. Divine,et al.  Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. , 2010, The Journal of clinical endocrinology and metabolism.

[50]  D. Houlihan,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[51]  B. Zinman,et al.  Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. , 2010, The Journal of clinical endocrinology and metabolism.

[52]  K. Roy,et al.  A prospective randomized trial comparing the clinical and endocrinological outcome with rosiglitazone versus laparoscopic ovarian drilling in patients with polycystic ovarian disease resistant to ovulation induction with clomiphene citrate , 2010, Archives of Gynecology and Obstetrics.

[53]  C. Mullins,et al.  The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case–control study , 2010, Diabetologia.

[54]  T. Schöndorf,et al.  Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β‐cell function: results from the PioSwitch Study , 2009, Diabetes, obesity & metabolism.

[55]  S. Mudaliar,et al.  Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. , 2009, The Journal of clinical endocrinology and metabolism.

[56]  Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes , 2008, Geriatrics & gerontology international.

[57]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[58]  Philippe Giral,et al.  Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.

[59]  Peter Tontonoz,et al.  Fat and beyond: the diverse biology of PPARgamma. , 2008, Annual review of biochemistry.

[60]  E. Tuzcu,et al.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.

[61]  I. Dahabreh.  Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone , 2008, Clinical trials.

[62]  S. Yusuf,et al.  Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose , 2008, Diabetes Care.

[63]  B. Zinman,et al.  Rosiglitazone-Associated Fractures in Type 2 Diabetes , 2008, Diabetes Care.

[64]  J. Nestler.  Metformin for the treatment of the polycystic ovary syndrome. , 2008, The New England journal of medicine.

[65]  C. Zamboulis,et al.  Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes , 2008, Acta Diabetologica.

[66]  A. Grey.  Skeletal consequences of thiazolidinedione therapy , 2008, Osteoporosis International.

[67]  K. Cusi,et al.  Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. , 2007, Journal of hepatology.

[68]  R. Nesto,et al.  Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials , 2007, The Lancet.

[69]  Yoon K Loke,et al.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.

[70]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[71]  Y. Miyazaki,et al.  Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus , 2007, Clinical pharmacology and therapeutics.

[72]  D. Betteridge,et al.  Effects of pioglitazone on lipid and lipoprotein metabolism , 2007, Diabetes, obesity & metabolism.

[73]  M. Falagas,et al.  Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. , 2007, American heart journal.

[74]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[75]  L. Suva,et al.  Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. , 2007, Endocrinology.

[76]  T. Buchanan.  (How) Can We Prevent Type 2 Diabetes? , 2007, Diabetes.

[77]  A. Skene,et al.  The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. , 2007, Journal of the American College of Cardiology.

[78]  Huiman X Barnhart,et al.  Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. , 2007, The New England journal of medicine.

[79]  D. Riche,et al.  Thiazolidinediones and Risk of Repeat Target Vessel Revascularization Following Percutaneous Coronary Intervention , 2007, Diabetes Care.

[80]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[81]  S. Haffner,et al.  Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.

[82]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[83]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[84]  R. DeFronzo,et al.  Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome , 2006, Clinical pharmacology and therapeutics.

[85]  T. Buchanan,et al.  Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. , 2006, Diabetes.

[86]  F. Ovalle,et al.  Long‐term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes , 2006, Diabetes, obesity & metabolism.

[87]  A. Birmingham,et al.  The Practice Committee of the American Society for Reproductive Medicine and the Practice Committee of the Society for Assisted Reproductive Technology , 2006 .

[88]  G. Luc,et al.  The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients , 2006, Diabetologia.

[89]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[90]  Reena Rao,et al.  Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption , 2005, Nature Medicine.

[91]  S. Kihara,et al.  Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. , 2005, American journal of hypertension.

[92]  H. Ginsberg,et al.  Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus , 2005 .

[93]  A. Parfitt,et al.  Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. , 2005, Endocrinology.

[94]  H. Krumholz,et al.  Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study , 2005, Circulation.

[95]  H. Ginsberg,et al.  Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. , 2005, The Journal of clinical investigation.

[96]  R. DeFronzo,et al.  A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. , 2004, Archives of internal medicine.

[97]  T. Elasy,et al.  Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: a consensus statement from the American Heart Association and American Diabetes Association Response to Nesto , 2004 .

[98]  A. Häkkinen,et al.  Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.

[99]  M. Burnier,et al.  Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. , 2004, The Journal of clinical endocrinology and metabolism.

[100]  D. Thompson,et al.  Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. , 2004, The American journal of medicine.

[101]  A. Scheen.  Combined Thiazolidinedione-Insulin Therapy , 2004, Drug safety.

[102]  S. Ito,et al.  Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. , 2003, The Journal of clinical endocrinology and metabolism.

[103]  A. Festa,et al.  Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[104]  J. Manson,et al.  Menstrual cycle irregularity and risk for future cardiovascular disease. , 2002, The Journal of clinical endocrinology and metabolism.

[105]  A. Brett.  Can We Prevent Type 2 Diabetes , 2001 .

[106]  M. Matsuda,et al.  Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. , 2001, Diabetes care.

[107]  J. Henney.  Infant Pneumococcal Vaccine , 2000 .

[108]  J. Henney.  Withdrawal of Troglitazone and Cisapride , 2000 .

[109]  R. DeFronzo,et al.  Metformin: A review of its metabolic effects , 1998 .

[110]  M. Breyer,et al.  Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. , 1997, American journal of physiology. Renal physiology.

[111]  S. Franks,et al.  Polycystic ovary syndrome. , 1995, Archives of disease in childhood.

[112]  S. Nightingale,et al.  From the Food and Drug administration. , 1990, JAMA.